文献速递淋巴瘤

抑制NAMPT靶向DNA损伤反应使TP53突变套细胞淋巴瘤对烷化剂化疗增敏

Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.
PubMed 文献 · Blood Adv · 2026-01-01

TP53突变套细胞淋巴瘤(MCL)化疗反应差、早期进展,亟需新疗法。NAMPT在MCL细胞系和患者组织中过表达,其抑制剂KPT-9274在TP53突变与野生型MCL细胞中均降低活力并诱导凋亡。机制上,TP53突变细胞中NAMPT抑制通过破坏DNA损伤反应(DDR)通路触发合成致死,而TP53野生型细胞中则选择性抑制B细胞受体(BCR)信号和免疫检查点激活。体内研究证实基于NAMPT的组合在TP53突变异种移植瘤中实现显著肿瘤消退而不加重毒性。

要点

  • NAMPT在MCL细胞系和患者组织中过表达,是潜在治疗靶点。
  • TP53突变MCL中NAMPT抑制触发DDR通路破坏的合成致死。
  • TP53突变细胞对烷化剂和DDR靶向治疗增敏,野生型则可能克服BTK抑制剂耐药。

核心结论

  • NAMPT是TP53突变MCL中靶向DNA损伤反应以增敏烷化剂化疗的双情境治疗节点。

研究设计与样本

  • 研究使用MCL细胞系和患者组织评估NAMPT表达,并在体外和体内(异种移植瘤)模型测试NAMPT抑制剂KPT-9274单药及联合治疗。

主要发现

  • NAMPT抑制剂KPT-9274在TP53突变和野生型MCL细胞中均降低活力并诱导凋亡。
  • TP53突变细胞中NAMPT抑制通过破坏DDR通路触发合成致死,并显著增敏烷化剂和DDR靶向治疗。
  • TP53野生型细胞中NAMPT抑制选择性抑制BCR信号和免疫检查点激活,并可能克服BTK抑制剂耐药。
  • 体内研究显示基于NAMPT的组合在TP53突变异种移植瘤中实现显著肿瘤消退且不加重毒性。

临床怎么用

  • 基于TP53状态指导NAMPT抑制剂联合烷化剂或DDR靶向治疗,用于高危TP53突变MCL以克服化疗耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with TP53 mutant mantle cell lymphoma (MCL) face poor chemotherapy response and early progression, requiring novel therapies. Nicotinamide phosphoribosyl transferase (NAMPT), the rate-limiting nicotinamide adenine dinucleotide salvage enzyme overexpressed in MCL cell lines and patient tissues, emerges as a therapeutic target. The NAMPT inhibitor KPT-9274 reduced viability and induced apoptosis in MCL cells irrespective of TP53 status. Mechanistic studies reveal a striking dichotomy: in TP53 mutant cells, NAMPT inhibition triggers synthetic lethality through catastrophic DNA damage response (DDR) pathway disruption, whereas in TP53 wild-type cells, it selectively suppresses B-cell receptor (BCR) signaling and immune checkpoint activation. This biological divergence translates to clinically actionable synergies: TP53 mutant cells exhibit marked sensitization to alkylating agents and DDR-targeting therapies, whereas TP53 wild-type models show potential for overcoming BTK inhibitor resistance. In vivo studies confirm that NAMPT-based combinations achieve profound tumor regression in TP53 mutant xenografts without exacerbating toxicity. Our findings establish NAMPT as a dual-context therapeutic node, providing a precision medicine framework to circumvent chemoresistance in high-risk MCL. These results advocate for the clinical evaluation of TP53 status-guided NAMPT inhibitor combinations to address this unmet oncologic challenge.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Li N, Liu Y, Zhang L, et al. Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma. Blood Adv. 2026. PMID: 41428986. doi:10.1182/bloodadvances.2025016765

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。